Insmed Inc

Stock Chart, Company Information, and Scan Results

$144.46(as of Nov 19, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Insmed Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$144.46
Ticker SymbolINSM
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees1,664
CountyUSA
Market Cap$26,281.8M
EBIDTA-611.0M
10-Day Moving Average121.90
P/E Ratio-52.19
20-Day Moving Average112.72
Forward P/E Ratio107.53
50-Day Moving Average110.86
Earnings per Share-2.81
200-Day Moving Average122.61
Profit Margin-19.13%
RSI77.39
Shares Outstanding219.4M
ATR6.61
52-Week High212.75
Volume14,385,785
52-Week Low90.39
Most Recent Support Level118.44
Book Value726.2M
Most Recent Resistance Level124.92
P/B Ratio43.52
Upper Keltner127.58
P/S Ratio20.80
Lower Keltner97.85
Debt-to-Equity Ratio1.02
Next Earnings DateUnknown
Cash Surplus-200.0M
Next Ex-Dividend DateUnknown

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed Inc In Our Stock Scanner

As of Nov 19, 2026
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.